MoonLake Immunotherapeutics (MLTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MoonLake Immunotherapeutics (MLTX) closed at USD 10.14 on 2026-10-14, a change of +3.3 % over the past year, with a market capitalization of USD 873.19M.

MoonLake Immunotherapeutics recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MoonLake Immunotherapeutics key figures

Previous close

USD 10.14 (2026-10-14)

1-year change

+3.3 %

Market cap

USD 873.19M

Enterprise value

USD 437.7M

P/E ratio (trailing)

-2.71

P/E ratio (forward)

-3.08

EPS (trailing)

-3.78

EPS (forward)

-3.33

PEG ratio

n/a

Price to book

2.00

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.71

Employees

130

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MoonLake Immunotherapeutics and compare it with other stocks.